

Table D-2. Comparative studies, categorical measures

Author, year, PMID	Arm (N)	DM %	CMS %	Dyslipidemia % (definition)	HTN % (definition)	Coronary revasc. %	CKD % (definition)	MI, AMI % (definition)	CHF % (definition)	Stroke (CVA) % (definition)	PVD %	Carotid revascularization % (definition)	SVT or Afib % (def.)	Ventricular tachyarrhythmia % (definition)
Baxheinrich, 2012, 22894911	ALA (40)		100											
	Placebo (41)		100											
Bosch, 2012, 22686415	"Fish oil" (DHA+EPA) (6281)				78.7									
	Placebo (6255)				80.3									
Brinton, 2013, 23835245	EPA [4g/day] (226)	73												
	EPA [2g/day] (234)	73												
	Placebo (227)	73												
Brouwer, 2006, 16772624	Total (273)													
	"Fish oil" (DHA+EPA) (273)	17			53 (>=160/95 mm Hg in repeated measurements, or patients taking anti-hypertensive medication)			73 (ischemic heart disease)					26 (AFib)	75

Author, year, PMID	Arm (N)	DM %	CMS %	Dyslipidemia % (definition)	HTN % (definition)	Coronary revasc. %	CKD % (definition)	MI, AMI % (definition)	CHF % (definition)	Stroke (CVA) % (definition)	PVD %	Carotid revascularization % (definition)	SVT or Afib % (def.)	Ventricular tachyarrhythmia % (definition)
Brouwer, 2006,	Placebo (273)	15			49 (>=160/95 mm Hg in repeated measurements, or patients taking antihypertensive medication)			79 (ischemic heart disease)					25 (AFib)	76
Burr, 2003, 12571649	Fish + Fish oil (1571)	12.5			48.6			49.7						
	No intervention (1543)	12.3			47.4			50.2						
Burr, 1989, 2571009	Fish + Fish oil (1015)				22.7			100						
	No intervention (1018)				24.6			100						
Carrepeiro, 2011, 21561620	Total (43)	0		50 (on statins)			0					0		
Caslake, 2008, 18779276	Total (312)	0		0 (fasting total cholesterol a TAG concentrations of >8.0 a 3.0 mmol/L, respectively)				0 (MI in the previous 2 years)						
Ebrahimi, 2009, 19593941	Total (89)													
	"Fish oil" (DHA+EPA) (47)		100											

Author, year, PMID	Arm (N)	DM %	CMS %	Dyslipidemia % (definition)	HTN % (definition)	Coronary revasc. %	CKD % (definition)	MI, AMI % (definition)	CHF % (definition)	Stroke (CVA) % (definition)	PVD %	Carotid revascularization % (definition)	SVT or Afib % (def.)	Ventricular tachyarrhythmia % (definition)
	No intervention (42)		100											
Einvik, 2010, 20389249	"Fish oil" (DHA+EPA) (282)	15		20 (treated hyperlipidemia)	27 (treated hypertension)									
	Placebo (281)	14		19 (treated hyperlipidemia)	29 (treated hypertension)									
	Placebo (68)	15			32 (treated hypertension)			18						
	Placebo (71)	14			26 (treated hypertension)			18						
	"Fish oil" (DHA+EPA) (70)	13			31 (treated hypertension)			17						
	"Fish oil" (DHA+EPA) (69)	13			32 (treated hypertension)			18						
Eritsland, 1996, 8540453	"Fish oil" (DHA+EPA) (260)	4.2			20									
	No intervention (251)	9.6			24.7									
Galan, 2010, 21115589	Total (2501)							46 (28 unstable angina)		26				

Author, year, PMID	Arm (N)	DM %	CMS %	Dyslipidemia % (definition)	HTN % (definition)	Coronary revasc. %	CKD % (definition)	MI, AMI % (definition)	CHF % (definition)	Stroke (CVA) % (definition)	PVD %	Carotid revascularization % (definition)	SVT or Afib % (def.)	Ventricular tachyarrhythmia % (definition)
	"Fish oil" (DHA+EPA) (620)							45.2 (28.4 unstable angina)		26.4				
	"Fish oil" (DHA+EPA) (633)							47.4 (29.2 unstable angina)		23.4				
	Placebo (622)							46.3 (27.0 unstable angina)		26.7				
	Placebo (626)							45.0 (29.4 unstable angina)		25.6				
Holman, 2009, 19002433	Total (658)	100												
Kastelein 2014 24528690	Placebo (98)	30.3			64.6									
	"Fish oil" (DHA+EPA) (99)	39			69									
	"Fish oil" (DHA+EPA) (97)	44.6			68.3									
	"Fish oil" (DHA+EPA) (99)	36.4			67.7									
Kromhout, 2010, 20929341	All n3 PUFAs (ALA+DHA+EPA) (1212)	20.2												

Author, year, PMID	Arm (N)	DM %	CMS %	Dyslipidemia % (definition)	HTN % (definition)	Coronary revasc. %	CKD % (definition)	MI, AMI % (definition)	CHF % (definition)	Stroke (CVA) % (definition)	PVD %	Carotid revascularization % (definition)	SVT or Afib % (def.)	Ventricular tachyarrhythmia % (definition)
	"Fish oil" (DHA+EPA) (1192)	22												
	ALA (1197)	21.2												
	Placebo (1236)	20.1												
Leaf, 2005, 16267249	"Fish oil" (DHA+EPA) (200)					76 (coronary artery disease)							18 (history of Afib)	
	Placebo (202)												18.8 (history of Afib)	
Lungershausen, 1994, 7852747	Total (42)				100									
Macchia, 2013, 23265344	Placebo (297)	14.7			90.8					4.4			100	
	"Fish oil" (DHA+EPA) (289)	11.1			92.2					5			100	
Maki, 2013, 23998969	Placebo (211)	72.6			87.9									
	All n3 PUFAs (ALA+DHA+EPA) [2 g] (209)	73.5			87									
	All n3 PUFAs (ALA+DHA+EPA) [4 g] (207)	68.5			83.8									
Marchioli, 2002, 11997274, Italy	"Fish oil" (DHA+EPA) (5666)	14.2						11.6						18.8

Author, year, PMID	Arm (N)	DM %	CMS %	Dyslipidemia % (definition)	HTN % (definition)	Coronary revasc. %	CKD % (definition)	MI, AMI % (definition)	CHF % (definition)	Stroke (CVA) % (definition)	PVD %	Carotid revascularization % (definition)	SVT or Afib % (def.)	Ventricular tachyarrhythmia % (definition)
	No intervention (5668)	15						11.9						19.4
Natvig, 1968, 5756076	Placebo (6690)							0.13						
	ALA (6716)							0.15						
Nilsen, 2001, 11451717	"Fish oil" (DHA+EPA) (150)	32.9			28.6	8.0		21.3 (previous MI)	10.0 (heart failure)					
	Placebo (150)	8.7			22.8	10.1		25.3 (previous MI)	7.4 (heart failure)					
Nodari, 2011, 21844082	All n3 PUFAs (ALA+DHA+EPA) (100)	36			47									
	Placebo (99)	33.6			40.4									
	"Fish oil" (DHA+EPA) (67)	10.4												
	Placebo (66)	23												
Oh, 2014, 25147070	Placebo (42)	5	36	100										
	"Fish oil" (DHA+EPA) [1g] (44)	7	36	100										
	"Fish oil" (DHA+EPA) [2g] (43)	33	7	100										
	"Fish oil" (DHA+EPA) [4g] (44)	36	5	100										
Olano-Martin, 2010, 19748619	Total (38)	0						0						
Pieters 2015, 25226826	Total (32)			100										

Author, year, PMID	Arm (N)	DM %	CMS %	Dyslipidemia % (definition)	HTN % (definition)	Coronary revasc. %	CKD % (definition)	MI, AMI % (definition)	CHF % (definition)	Stroke (CVA) % (definition)	PVD %	Carotid revascularization % (definition)	SVT or Afib % (def.)	Ventricular tachyarrhythmia % (definition)
Raitt, 2005, 15956633	"Fish oil" (DHA+EPA) (100)	46			46			55						64
	Placebo (100)	23			55			56						69
Rauch, 2010, 21060071	All n3 PUFAs (ALA+DHA+EPA) (1919)	27.6		50.5	66.9			100		5.8				
	Placebo (1885)	26.4		48.5	66.1			13.5		5.1				
Rodriguez-Leyva, 2013, 24126178	All n3 PUFAs (ALA+DHA+EPA) (45)	31.8			75.4									
	Placebo (42)	26.1			69.2									
Roncaglioni, 2013, 23656645	"Fish oil" (DHA+EPA) (6244)	59.6			84.6					4.7				
	No intervention (6269)	60.2			84.6					4.8				
Sacks, 1995, 7759696	"Fish oil" (DHA+EPA) (175)	16				52		55						
	Placebo (175)	11				43		57						
Shaikh, 2014, 25185754	"Fish oil" (DHA+EPA) (56)	10.7			32.1									
	Placebo (54)	14.8			31.5									
Shidfar, 2003, 12847992	Total (68)			100										

Author, year, PMID	Arm (N)	DM %	CMS %	Dyslipidemia % (definition)	HTN % (definition)	Coronary revasc. %	CKD % (definition)	MI, AMI % (definition)	CHF % (definition)	Stroke (CVA) % (definition)	PVD %	Carotid revascularization % (definition)	SVT or Afib % (def.)	Ventricular tachyarrhythmia % (definition)
Sirtori, 1997, 9174486	All n3 PUFAs (ALA+DHA+EPA) (470)	44 (diagnosed with diabetes for 2 y, who were in satisfactory metabolic control)		100 (triacylglycerol 2.26-4.52 mmol/L, or 200-400 mg/dL)		68 (treated with antihypertensive drugs or SBP >= 160 mm Hg, DBP >= 95 mm Hg, or both)		0 (MI in the preceding 3 months)						
	Placebo (465)	45 (diagnosed with diabetes for 2 y, who were in satisfactory metabolic control)		100 (triacylglycerol 2.26-4.52 mmol/L, or 200-400 mg/dL)		68 (treated with antihypertensive drugs or SBP >= 160 mm Hg, DBP >= 95 mm Hg, or both)		0 (MI in the preceding 3 months)						
Tatsuno, 2013, 24314359	"Fish oil" (DHA+EPA) [2 g/day] (165)	30.3 (Including impaired glucose tolerance.)			66.7									

Author, year, PMID	Arm (N)	DM %	CMS %	Dyslipidemia % (definition)	HTN % (definition)	Coronary revasc. %	CKD % (definition)	MI, AMI % (definition)	CHF % (definition)	Stroke (CVA) % (definition)	PVD %	Carotid revascularization % (definition)	SVT or Afib % (def.)	Ventricular tachyarrhythmia % (definition)
	"Fish oil" (DHA+EPA) [4 g/day] (171)	36.8 (Including impaired glucose tolerance)			67.3									
	EPA [1.8 g/day] (167)	42.5 (Including impaired glucose tolerance)			68.9									
Tatsuno, 2013, 23725919	"Fish oil" (DHA+EPA) [2 g/day] (206)	30.1 (Including impaired glucose tolerance)			59.7									
	"Fish oil" (DHA+EPA) [4 g/day] (210)	33.3 (Including impaired glucose tolerance)			60.5									

Author, year, PMID	Arm (N)	DM %	CMS %	Dyslipidemia % (definition)	HTN % (definition)	Coronary revasc. %	CKD % (definition)	MI, AMI % (definition)	CHF % (definition)	Stroke (CVA) % (definition)	PVD %	Carotid revascularization % (definition)	SVT or Afib % (def.)	Ventricular tachyarrhythmia % (definition)
	EPA [1.8 g/day] (195)	34.4 (Including impaired glucose tolerance)			67.2									
Tavazzi, 2008, 18757090	"Fish oil" (DHA+EPA) (3494)	28.4				17.6 (CABG); 12.2 (PCI)		41.8	50 (admission for HF in the previous year)	4.8	8.4			7.1 (implantable cardiac defibrillators)
	Placebo (3481)	28.2				18.9 (CABG); 12.7 (PCI)		41.6	(admission for HF in the previous year)	5.1	9.1			7.2 (implantable cardiac defibrillators)
Tierney, 2011, 20938439	Total (206)		100											
Yokoyama, 2007, 17398308	EPA (9326)	16		100		5		6						
	All arms (XO study) (9319)	16		100		5		5						